Amgen (AMGN) reported Q2 adjusted earnings late Tuesday of $6.29 per diluted share, up from $6.02 a year earlier.

Analysts polled by FactSet expected $5.62.

Revenue for the quarter ended June 30 was $10.05 billion, up from $9.18 billion a year earlier.

Analysts expected $9.43 billion.

For the full-year 2026, the company now expects adjusted EPS of $22.30 to $23.50 on revenue of $38.2 billion to $39.4 billion, compared with its prior guidance of adjusted EPS of $21.70 to $23.10 on revenue of $37.10 billion to $38.50 billion.

Analysts expect $22.36 and $37.74 billion, respectively.